In the FIGHT trial on patients hospitalized for HFrEF, Liraglutide did not show benefit on time to death, time to rehospitalization for heart failure, and time-averaged proportional change in N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels from baseline to 180 days [51]
Regenerons Phase II COURAGE program is testing whether add-on therapies, such as the antibody trevogrumab, can help people on GLP-1 therapy lose more fat while preserving lean mass
National Institute of Diabetes and Digestive and Kidney Diseases: Prescription Medications to Treat Overweight and Obesity Obesity Medicine Association: Top Weight Loss Medications Sean Hashmi, MD Medical Reviewer Sean Hashmi, MD, is an experienced nephrologist and obesity medicine specialist based in Southern California
Morning alertness often improves before subjective sleep quality does, because deep sleep restoration begins benefiting recovery even before you consciously perceive the sleep as better